Otic Suspension of Ciprofloxacin (OTO-201) Tested in Pediatrics

This article originally appeared here.
Otic suspension of ciprofloxacin safe, effective for children undergoing tympanostomy tube placement
Otic suspension of ciprofloxacin safe, effective for children undergoing tympanostomy tube placement

HealthDay News — Intraoperative administration of an otic suspension of ciprofloxacin (OTO-201) appears to be safe and effective for children requiring tympanostomy tube placement (TTP), according to research published online March 17 in JAMA Otolaryngology-Head & Neck Surgery.

Eric A. Mair, MD, from Charlotte Eye, Ear, Nose, and Throat Associates in North Carolina, and colleagues conducted two identically designed prospective phase 3 trials involving 532 patients aged 6 months to 17 years. Patients with confirmed bilateral middle ear effusions on the day of TTP were randomly allocated to receive TTP only (175 patients) or TTP with OTO-201 injection (357 patients).

The researchers found that the cumulative proportion of treatment failures at day 15 was 24.6 and 21.3% in trials 1 and 2, respectively, in the OTO-201 groups, compared with 44.8 and 45.5%, respectively, in the TTP-only group. Otorrhea-only treatment failures at day 15 were 11.7% in the OTO-201 group versus 25.3% in the TTP-only group in trial 1, and 9.6 and 33.0%, respectively, in trial 2. In both trials, the odds of otorrhea-only failure were significantly reduced in the OTO-201 groups compared with the TTP-only groups (age-adjusted odds ratios, 0.38 and 0.19, respectively; both P < 0.001).

"Two large phase 3 randomized clinical trials demonstrate the safety and efficacy of a single intraoperative administration of OTO-201 for middle ear effusion at the time of TTP," the authors write.

Several authors disclosed financial ties to Otonomy Inc., which manufactures OTO-201 and funded the study.

Abstract
Full Text (subscription or payment may be required)

Loading links....